

Noxopharm completes SOF-SKN™ formulation as clinical trial approaches

Highlights

- Critical step in drug development process finalised
- SOF-SKN™ formulation effectively delivers active drug to target tissues
- Growing interest in Sofra™ platform


Sydney, 17 September 2024: Innovative biotech company **Noxopharm Limited (ASX:NOX)** announces it has completed formulation development for its [SOF-SKN™](#) lupus medication in advance of the upcoming [HERACLES clinical trial](#).

Formulation is a critical step in the drug development process as it represents how SOF-SKN will be administered to participants in the trial, and also supports the efficacy of the drug itself.

SOF-SKN contains a proprietary ultra-short oligonucleotide that binds to specific inflammation sensors in the body to reduce inflammation at its source.

After a systematic and highly streamlined development process, Noxopharm has now finalised a topical formulation that has been specifically designed to deliver therapeutic levels of the drug as [deep as the dermis](#) – the layer of skin that contains the specific inflammation sensors targeted by SOF-SKN.

Figure: Skin layers with immune cells



The formulation has several beneficial characteristics, including enabling an even release and delivery of the active drug ingredient into the skin in a consistent manner. It can also deliver sustained concentrations over 48 hours when compared to a number of other formulations that were tested.

SOF-16 – Mean Dermis Concentration




Figure 1: SOF-16 (blue line), the active ingredient of SOF-SKN, was delivered in high concentrations into the dermis and maintained concentration levels over 48 hours.

As noted in its June 2024 quarterly update, Noxopharm’s Sofra™ technology platform is attracting international attention and [several material transfer agreements](#) (MTAs) with mid-size to multi-billion dollar companies are already in place. The value of an MTA lies in the fact that it represents an essential step along the path to potential commercialisation. Each of the companies that signed an MTA with Noxopharm is investing its own resources to assess the potential of a number of novel Sofra assets, and a variety of use cases are being explored. This engagement supports Noxopharm’s innovative approach and opens pathways to commercial opportunities.

Noxopharm CEO Dr Gisela Mautner said: “Finalising the SOF-SKN formulation is a major step as we approach our first clinical trial with this innovative technology. The pieces of the puzzle are all falling into place, and we are now moving forward with other HERACLES trial preparations while continuing to showcase the Sofra platform to a wide range of external stakeholders around the world.”

Interest in RNA-related technologies is expanding rapidly following the success of the major COVID-19 vaccines during the recent pandemic, as they have the potential to create much-needed new drugs and other vaccines for numerous diseases. According to Precedence Research, the mRNA market in 2022 was US\$40 billion and is expected to reach US\$137 billion by 2032 at a compound annual growth rate of 13%. This burgeoning market offers substantial growth potential for Noxopharm’s Sofra platform.

-ENDS-



About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.